Deciphex Raises $11.5 Million in Series B  

by Kay Aloha Villamor in May 20th, 2022

Deciphex, a leading provider of pathology software and services, announced that it closed an $11.5 million Series B funding round. 

The round was led by ACT Venture Capital, with Charles River Laboratories, Novartis, IRRUS Investments, Nextsteps Capital, HBAN Medtech Syndicate, and other current investors also participating. 

The company will leverage the funding to continue driving global growth and consolidate its position as a leader in revolutionizing clinical and non-clinical pathology, through the use of digital pathology and artificial intelligence (AI), along with supporting ongoing expansion in the UK, Canada, and the Middle East.

Company: Deciphex Limited

Raised: $11.5M

Round: Series B

Funding Month: May 2022

Lead Investors: ACT Venture Capital

Additional Investors: Charles River Laboratories, Novartis, IRRUS Investments, Nextsteps Capital, and HBAN Medtech Syndicate

Company Website:

Software Category: Pathology Software

About the Company: Founded in 2017 Deciphex is an Irish-based, software company focused on developing digital pathology-based software and services for clinical and research pathology. Deciphex is a rapidly scaling player in the emerging pathology computer-aided diagnostics sector that uses digital pathology and AI to accelerate pathology diagnostics, improving productivity and patient outcome. Deciphex ambition is to network and accelerate the world's pathologists. We believe that digital pathology combined with artificial intelligence will help make pathologists work more efficiently, offering a solution to the pending challenges in supply/demand in pathology services. Deciphex plans to be at the forefront of this revolution with cleverly positioned solutions that deliver on the biggest problems facing pathology today.




Your cart